Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
-

-

-
-
-
?2.00
 
WKN: A3D3E9 / Symbol: RSLS / Name: Reshape Lifesciences / Stock / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Reshape Lifesciences Inc. Stock

With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Reshape Lifesciences Inc. stock is not clear.
However, we have a potential of -59.43% for Reshape Lifesciences Inc. as the target price of 2 € is below the current price of 4.93 €.
For the coming years our community has positive and negative things to say abot the Reshape Lifesciences Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.

Pros and Cons of Reshape Lifesciences Inc. in the next few years

Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-01

At a first glance, a noteworthy aspect of Reshape Lifesciences' financial situation is the lack of available data in some important areas. For instance, the firm's market capitalization, P/E ratio, and EBITDA are all missing, making it challenging to form a precise evaluation of the company's valuation or profitability.

When analyzing Reshape Lifesciences' financials, several pros and cons emerge that warrant further consideration.

The foremost positive aspect highlighted from the data is the company's gross profit TTM that stands at $8,348,000. This number suggests that the company is able to generate profit from its core business operations, which is a vital sign of a healthy business.

Comments

Buy ReShape Lifesciences Inc.
Show more

Buy Obalon Therapeutics Inc.
Show more